CareFusion Aims To Accelerate Infusion Sales Growth Post Baxter Recall
This article was originally published in The Gray Sheet
Executive Summary
CareFusion expects to grow infusion system sales at a brisk rate in fiscal 2011, in part by capitalizing on Baxter's ongoing infusion pump recall, the firm said during its Aug. 10 earnings call
You may also be interested in...
BD Expects Alaris Infusion Pump To Return To US Market Next Year
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
CareFusion: Increased Infusion Sales Offset By Light Flu Season
CareFusion had mixed results last quarter, combining increased infusion pump sales offset by reduced respiratory revenues, due, in part, to a lighter flu season, the firm said Nov. 2.
CareFusion: Increased Infusion Sales Offset By Light Flu Season
CareFusion had mixed results last quarter, combining increased infusion pump sales offset by reduced respiratory revenues, due, in part, to a lighter flu season, the firm said Nov. 2.